{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:36:39Z","timestamp":1783740999253,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"The University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.gore.2025.101797","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T11:10:37Z","timestamp":1750849837000},"page":"101797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2813-2123","authenticated-orcid":false,"given":"Michael","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amma","family":"Asare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Dockery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis T.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gore.2025.101797_b0005","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.gore.2025.101797_b0010","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-024-03080-9","article-title":"Summary of research: efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: Post Hoc analysis of DESTINY-PanTumor","author":"Oaknin","year":"2025","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.gore.2025.101797_b0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2025.101797_b0020","unstructured":"HER2 Genetic Link to Breast Cancer. September 15, 2014, Accessed March 29, 2025. https:\/\/www.cancer.gov\/research\/progress\/discovery\/her2."},{"issue":"20","key":"10.1016\/j.gore.2025.101797_b0025","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2025.101797_b0030","unstructured":"Center for Drug Evaluation, Research. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. U.S. Food and Drug Administration. August 9, 2024. Accessed March 30, 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2."},{"issue":"15","key":"10.1016\/j.gore.2025.101797_b0035","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2025.101797_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer","volume":"198","author":"Mart\u00edn","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.gore.2025.101797_b0045","doi-asserted-by":"crossref","first-page":"e7168","DOI":"10.1002\/cam4.7168","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: real-life data from the temporary use authorization program in France","volume":"13","author":"Petit","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.gore.2025.101797_b0050","unstructured":"ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki). ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) | Official HCP Site. Accessed June 11, 2025. https:\/\/www.enhertuhcp.com\/en\/ihc3-plus-metastatic-solid-tumors."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925001225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925001225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:17:42Z","timestamp":1766413062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578925001225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":10,"alternative-id":["S2352578925001225"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.101797","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.101797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101797"}}